A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA‐damaging agents such as temozolomide. The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects. METHODS: A single‐arm, open‐label, phase 2 study was performed to investigate the disease control rate (DCR) after 2 cycles of veliparib plus temozolomide in patients with metastatic colorectal cancer (mCRC) refractory to all standard therapies. Fifty patients received temozolomide (150 mg/m 2/d) on days 1 to 5 and veliparib (40 mg twice daily) on days 1 to 7 of each 28‐day cycle. Another 5 patients with mismatch repair–deficient (dMMR) tumors were also enrolled. Twenty additional patients were then treated with temozolomide at 200 mg/m 2/d. Archived tumor specimens were used for immunohistochemistry to assess mismatch repair, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and O(6)‐methylguanine‐DNA methyltransferase (MGMT) protein expression levels. RESULTS: The combination was well tolerated, although some patients required dose reductions for myelosuppression. The primary endpoint was successfully met with a DCR of 24% and 2 confirmed partial responses. The median progression‐free survival was 1.8 months, and the median overall survival was 6.6 months. PTEN protein expression and MGMT protein expression were not predictors of DCR. There was also a suggestion of worse outcomes for patients with dMMR tumors. CONCLUSIONS: In this heavily pretreated mCRC population, a combination of veliparib and temozolomide was well tolerated with temozolomide doses up to 200 mg/m 2/d, and it was clinically active. PARP inhibitor–based therapy merits further exploration in patients with mCRC. Cancer 2018;124:2337‐46. © 2018 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“Age, median (range), y 56 (35-72) 54 (35-72) 58.”
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“Age, median (range), y 56 (35-72) 54 (35-72) 58.”
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 1×
“Loss 30 (40) 23 (46) 7 (35) 0 (0) No loss 19 (25) 16 (32) 3 (15) 0 (0)”
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540 · cited 1×
“Age, median (range), y 56 (35-72) 54 (35-72) 58.”
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122 · cited 6×
“1 51 (68) 33 (66) 16 (80) 2 (40) 2 2 (3) 2 (4) 0 (0) 0 (0)”
InfluentialDePinho, R. A., & Polyak, K. (2004) · Nature Genetics · doi:10.1038/ng0904-932 · Cited by 91
Cited by
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon
Talele, T. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00829 · Cited by 424
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62
“NCT01051596 Pishvaian [135] II Heavily pretreated metastatic CRC Veliparib (ABT-888) + temozolomide 75 2/75 (2.”
BackgroundMethylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Metadata
- Authors
- Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., & Brody, J. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2018-03-26
- Volume
- 124
- Issue
- 11
- Pages
- 2337-2346
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2794157907
- Cited by
- 69
- References
- 8
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. https://app.cochat.ai/papers/10.1002/cncr.31309
- The paper
- Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., & Brody, J. R. (2018). A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. https://doi.org/10.1002/cncr.31309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.